Abbott/Wyeth drug monitoring test
This article was originally published in The Gray Sheet
Executive Summary
510(k) submission for Abbott's automated test to monitor Rapamune (sirolimus) renal transplant anti-rejection drug response is submitted to FDA under a 2003 collaboration with drug maker Wyeth. Manufacturing partner Axis-Shield is responsible for regulatory clearance. The test will run on Abbott's IMx automated immunoassay analyzer. Abbott already offers tests for cyclosporine and tacrolimus immunosuppressant monitoring. FDA currently is preparing to issue guidance outlining Class II special controls for sirolimus test systems after recently approving Microgenics' Cedia sirolimus assay via the de novo review process (1"The Gray Sheet" Aug. 23, 2004, p. 17)...
You may also be interested in...
Regulatory News In Brief
Part 11: FDA plans to publish draft guidance on use of computerized systems in clinical trials by the end of August. The "Part 11" draft guidance will replace a guidance on the same topic published in April 1999 and align the guidelines with policy articulated in FDA's broader guidance released in August 2003: "Part 11, Electronic Records; Electronic Signatures - Scope and Application" (1"The Gray Sheet" Sept. 8, 2003, In Brief). The forthcoming draft guidance is expected to outline general principles that should be followed when computerized systems are used to create, modify, maintain, archive, retrieve or transmit clinical trial data to ensure that electronic records meet regulatory standards and requirements. Many of the guidance's general principles are expected to address clinical trial electronic record security...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.